Emily J Erbelding,etc.,al. A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. The Journal of Infectious Diseases 28 Feb 2018
A priority for the National Institute of Allergy and Infectious Diseases (NIAID) is development of an influenza vaccine providing durable protection against multiple influenza strains, including those that may cause a pandemic, i.e., a universal influenza vaccine. To invigorate research efforts, NIAID developed a strategic plan focused on knowledge gaps in three major research areas, as well as additional resources required to ensure progress towards a universal influenza vaccine. NIAID will use this plan as a foundation for future investments in influenza research and will support and coordinate a consortium of multidisciplinary scientists focused on accelerating progress towards this goal.
See Also:
Latest articles in those days:
- Emergence of Novel Reassortant H3N2 Avian Influenza Viruses in Southern China: Genetic Complexity and Pathogenicity in Chickens and Mice 21 minute(s) ago
- Pathological evidence of neurotropism and oculotropism in wild black-headed gulls naturally infected with H5N1 high pathogenicity avian influenza 26 minute(s) ago
- Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness 13 hours ago
- Genetic Characterization of Swine Influenza Viruses in Thailand in 2019-2025 Reveals Novel Reassortants 13 hours ago
- Outbreak dynamics of high pathogenicity avian influenza virus H5N1, clade 2.3.4.4b euBB, in black-headed gulls and common terns in Germany in 2023 13 hours ago
[Go Top] [Close Window]


